## Abstract We have found a new ^111^In‐bleomycin complex (BLMC), which has high affinity to tumor, does not bind to transferrin and is stable in vivo. Distribution in animals bearing glioma, hepatoma, or mammary adenocarcinoma at 48 hours showed: the ratios of tumor to blood, brain, heart, lung, l
Comparison of oncophilic radiopharmaceuticals, *I-fibrinogen, 67Ga- citrate, 111In-bleomycin, and *I-bleomycin in tumor-bearing mice
✍ Scribed by Gerald L. Denardo; Kenneth A. Krohn; Sally J. Denardo
- Publisher
- John Wiley and Sons
- Year
- 1977
- Tongue
- English
- Weight
- 556 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
The pharmacokinetics of E7Ga-citrate, "'In-bleomycin, *I-bleomycin, and *Ifibrinogen were compared in a murine KHJJ tumor model in order to assess their relative potential as agents for in vivo detection of cancer. Although all four agents have been reported to be clinically efficacious, in this tumor model, *Ifibrinogen and 67Ga-citrate had the greatest tumor accumulation with maximum concentrations of 11.7% and 10.5% respectively. However, both these radiopharmaceuticals cleared slowly from the blood and animal. The maximum tumor concentrations of "'In-bleomycin and *I-bleomycin were 2 -9% and 2.6% respectively, but *I-bleomycin had the advantage of rapid clearance from the blood and animal. E7Ga-citrate did not achieve its maximum tumor concentration until 24 hours after administration, whereas the other radiopharmaceuticals achieved maximum tumor concentration within several hours of administration. From these observations 'aaI-bleomycin seems to deserve clinical trials in patients. '%fibrinogen appears to have significant oncophilic potential if its clearance from the animal can be accelerated without altering its accumulation in the tumor.
C a n ~~r 40:2923-2929, 1977.
LTHOUGH SEVERAL ONCOPHILIC RADIO-
A pharmaceuticals, including "'In-bleomycin, "'I-fibrinogen, "'In-chloride, and '6Se-selenomethionine have been used for the in vivo detection of cancer generally, only "Ga-citrate has achieved widespread clinical use. The ability of "Ga, administered carrier-free as the citrate complex, to localize in some human and animal tumors to an extent sufficient to permit scintigraphic visualization of the lesions is now
From the
📜 SIMILAR VOLUMES